Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides

William H. Miller, Christine Hartmann-Siantar, Darrell Fisher, Marie Anne Descalle, Tom Daly, Joerg Lehmann, Michael R. Lewis, Timothy Hoffman, Jeff Smith, Peter D. Situ, Wynn A. Volkert

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular-targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimelry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for 90Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for 90Y to 1% for 177Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.

Original languageEnglish (US)
Pages (from-to)436-449
Number of pages14
JournalCancer Biotherapy and Radiopharmaceuticals
Issue number4
StatePublished - 2005


  • Pm
  • Ho
  • Lu
  • Re
  • Cu
  • Y
  • Beta-emitter dosimetry
  • MCNP
  • Medical Internal Radiation Dose (MIRD) estimates
  • Molecular targeted radionuclide therapy
  • Mouse model
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology


Dive into the research topics of 'Evaluation of beta-absorbed fractions in a mouse model for90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides'. Together they form a unique fingerprint.

Cite this